Autologous peripheral blood stem cell transplantation with high-dose therapy for anaplastic large cell lymphoma with progressive myelofibrosis.
- Author:
Na Ri LEE
1
;
Eun Kee SONG
;
Ho Young YHIM
;
Kyu Yun JANG
;
Sam Im CHOI
;
Chang Yeol YIM
;
Jae Yong KWAK
Author Information
1. Division of Hematology/Oncology and Internal Medicine, Chonbuk National University Medical School, Jeonju, Korea. jykwak@chonbuk.ac.kr
- Publication Type:Case Report
- Keywords:
Myelofibrosis;
Anaplastic large cell lymphoma;
Stem cell transplantation
- MeSH:
Anemia;
Bone Marrow;
Collagen;
Fibrosis;
Humans;
L-Lactate Dehydrogenase;
Lymphoma;
Lymphoma, Large-Cell, Anaplastic;
Megakaryocytes;
Peripheral Blood Stem Cell Transplantation;
Primary Myelofibrosis;
Reticulin;
Splenomegaly;
Stem Cell Transplantation;
Survival Rate
- From:Korean Journal of Medicine
2010;79(1):77-81
- CountryRepublic of Korea
- Language:English
-
Abstract:
Myelofibrosis is a myeloproliferative neoplasm characterized by abnormal bone marrow megakaryocyte proliferation with reticulin and collagen fibrosis, leukoerythroblastosis, anemia, increased level of serum lactate dehydrogenase and splenomegaly. Myelofibrosis associated with malignant lymphoma is rare and survival rates appear to have been poor. Herein, we describe our experience in a patient who remained in complete remission with high-dose therapy (HDT) with autologous peripheral blood stem cell transplantation (PBSCT) for ALK-negative ALCL presenting with rapidly progressing myelofibrosis.
